Day: July 24, 2025

TARRYTOWN, N.Y., July 24, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 13th annual Regeneron Prize for Creative Innovation (the “Regeneron Prize”), which recognizes and rewards outstanding creativity and talent among early-career scientists in biomedical research. Each year, top U.S. research universities nominate their most promising graduate students and postdoctoral fellows for this honor. These nominees are invited to develop and pitch their “dream projects” in biomedical science to a panel of Regeneron’s leading scientists, who evaluate the proposals for scientific merit, creativity and originality. This year’s winners are Alissandra L. Hillis, Ph.D., and Sreekar Mantena. Dr. Hillis is a postdoctoral fellow at the Massachusetts Institute of Technology (MIT), and...

TROY, Mich., July 24, 2025 (GLOBE NEWSWIRE) — Kelly, a leading global specialty talent solutions provider, will release its second-quarter earnings before the market opens on Thursday, August 7, 2025. In conjunction with its earnings release, Kelly will publish a financial presentation and host a live webcast of a conference call with financial analysts at 9 a.m. ET on August 7 to review the results from the quarter and answer questions. The presentation and a link to the live webcast will be accessible through the Company’s public website on the Investor Relations page under Events & Presentations. The webcast will be recorded, and a replay will be available within one hour of completion of the event through the same link as the live webcast. About Kelly Kelly Services, Inc. (Nasdaq: KELYA, KELYB) helps companies recruit...

-Leadership Updates- Vancouver, BC, July 24, 2025 (GLOBE NEWSWIRE) — American Tungsten Corp. (CSE:TUNG) (OTCQB:DEMRF) (FSE:RK9) (“American Tungsten” or the “Company”) is pleased to announce, further to its news releases of June 30, 2025 and July 17, 2025, the successful closing of its oversubscribed non-brokered private placement (the “Offering”). Pursuant to the Offering, the Company issued 14,000,000 common shares (the “Shares”) at a price of C$0.50 per Share raising gross proceeds of C$7,000,000. The strong demand from institutional investors and insiders underscores growing confidence in the Company’s vision, strategy, and momentum in the critical metals space. In consideration for providing certain finder’s services to the Company in connection with the Offering, the Company paid cash finder’s fees of an aggregate C$253,421.35...

– Peer-reviewed publication in Annals of Clinical and Translational Neurology highlights the use of the MSA Atrophy Index developed to diagnose and track disease progression in Multiple System Atrophy – MELBOURNE, Australia and SAN FRANCISCO, July 24, 2025 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an innovative neuroimaging measure developed in Alterity’s Biomarkers of Progression in Multiple System Atrophy (bioMUSE) Natural History Study was featured in the peer-reviewed journal Annals of Clinical and Translational Neurology. The publication, entitled “The MSA Atrophy Index (MSA-AI): An Imaging Marker for Diagnosis and Clinical Progression in Multiple...